8legs: Novo nordisk

Your Followed Topics

#1 out of 212.9K est. views86.53%

TIME reveals the 2026 TIME100 Health list, naming 100 influential figures in global health.
The selection was created after months of sourcing and expert consultation.
The list includes scientists, doctors, advocates, educators, and policy-makers.
TIME highlights notable advances in CRISPR therapy and cancer immunotherapies.
TIME notes global health funding shifts after reduced international aid funding.
The full TIME100 Health list is available for readers to explore.
TIME’s health coverage also features Must-Reads from TIME related to health.
The piece emphasizes leadership across global health sectors and roles.
The article is authored by TIME Health staff.

Vote 0

#2 out of 2

FDA says Novo Nordisk's Wegovy TV ad contains false or misleading claims about the drug's benefits.
Agency requests immediate action, including potential cessation of misleading ads.
FDA says ad implies greater weight loss and broader life benefits without evidence.
Agency notes improper risk information presentation in the ad.
Novo Nordisk says the ad has run since launch but is not the Super Bowl spot.
Wegovy is a key product as Novo Nordisk competes with Eli Lilly in the GLP-1 market.
Wegovy's launch makes it a focal point of Novo Nordisk's market strategy in obesity.
More than 170,000 Americans are taking Wegovy, per Novo Nordisk statements.
FDA's action follows Bloomberg reporting on the letter.
Novo Nordisk also faces legal action against Hims & Hers over compounded Wegovy.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.